Bioheng Therapeutics receives FDA clearance for Phase Ib/II trial of CTD402, a CD7-targeted universal CAR-T cell therapy for relapsed/refractory T-ALL/LBL patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.